| 10.82 0.22 (2.08%) | 10-07 15:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.27  |
1-year : | 17.2 |
| Resists | First : | 13.08 |
Second : | 14.72 |
| Pivot price | 11.49 |
|||
| Supports | First : | 10.41 |
Second : | 8.66 |
| MAs | MA(5) : | 10.75 |
MA(20) : | 11.82 |
| MA(100) : | 11.99 |
MA(250) : | 9.78 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 7.8 |
| RSI | RSI(14): 33.1 |
|||
| 52-week | High : | 15.35 | Low : | 6.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MGTX ] has closed above bottom band by 31.7%. Bollinger Bands are 37.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.94 - 11 | 11 - 11.06 |
| Low: | 10.38 - 10.45 | 10.45 - 10.51 |
| Close: | 10.5 - 10.61 | 10.61 - 10.71 |
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Tue, 06 Oct 2026
MeiraGTx Holdings PLC (MGTX) Insider Stuart Naylor Sells 27,659 Shares - GuruFocus
Tue, 06 Oct 2026
Form 4 MeiraGTx Holdings PLC For: 6 October By Investing.com - Investing.com UK
Tue, 06 Oct 2026
Meiragtx chief scientific officer sells $294,291 in stock By Investing.com - Investing.com UK
Tue, 06 Oct 2026
Officer Stuart Naylor proposes selling 27,659 MeiraGTx (NASDAQ: MGTX) shares worth $294K. - Stock Titan
Tue, 06 Oct 2026
The Technical Signals Behind (MGTX) That Institutions Follow - Stock Traders Daily
Thu, 01 Oct 2026
Meiragtx Holdings Plc (MGTX-Q) Stock Price and News - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 5.375e+007 (%) |
| Held by Institutions | 16.3 (%) |
| Shares Short | 4,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.9613e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 19.8 % |
| Operating Margin | 76 % |
| Return on Assets (ttm) | 38.6 % |
| Return on Equity (ttm) | 72.1 % |
| Qtrly Rev. Growth | 8 % |
| Gross Profit (p.s.) | 479.21 |
| Sales Per Share | 3.12992e+008 |
| EBITDA (p.s.) | 3.06575e+008 |
| Qtrly Earnings Growth | 0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 14 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 6 |
| Dividend | 0 |
| Forward Dividend | 3.74e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|